Mutations in the human phosphofructokinase muscle subunit gene (PFKM) are known to cause myopathy classified as glycogenosis type VII (Tarui disease). Previously described molecular defects include base substitutions altering encoded amino acids or resulting in abnormal splicing. We report a mutation resulting in phosphofructokinase deficiency in three patients from an Ashkenazi Jewish family. Using a reverse transcription PCR assay, PFKM subunit transcripts differing by length were detected in skeletal muscle tissue of all three affected subjects. In the longer transcript, an insertion of 252 nucleotides totally homologous to the structure of the 10th intron of the PFKM gene was found separating exon 10 from exon 11. In addition, two single base transitions were identified by direct sequencing: [exon 6; codon 95; CGA (Arg) to TGA (stop)] and [exon 7; codon 172; ACC (Thr) to ACT (Thr)] in either transcript. Single-stranded conformational polymorphism and restriction enzyme analyses confirmed the presence of these point substitutions in genomic DNA and strongly suggested homozygosity for the pathogenic allele. The nonsense mutation at codon 95 appeared solely responsible for the phenotype in these patients, further expanding genetic heterogeneity of Tarui disease. Transcripts with and without intron 10 arising from identical mutant alleles probably resulted from differential pre-mRNA processing and may represent a novel message from the PFKM gene.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40788PMC
http://dx.doi.org/10.1073/pnas.92.22.10322DOI Listing

Publication Analysis

Top Keywords

tarui disease
12
nonsense mutation
8
mutation phosphofructokinase
8
phosphofructokinase muscle
8
muscle subunit
8
subunit gene
8
ashkenazi jewish
8
pfkm gene
8
[exon codon
8
gene
4

Similar Publications

Article Synopsis
  • Glycogen Storage Disease Type VII (GSD VII) is a rare disorder caused by mutations in the PFKM gene, leading to various symptoms like muscle weakness and exercise intolerance due to issues in glycogen metabolism.
  • A case study of a 17-year-old Chinese woman highlighted significant muscle weakness, elevated creatine kinase levels, and glycogen deposition in her muscles, emphasizing the diagnostic challenges of GSD VII.
  • Whole genome and exome sequencing revealed two new mutations in the PFKM gene, enhancing our understanding of the disease and its symptoms, which can help improve diagnosis and treatment in the future.
View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the relationship between coagulopathy and patient outcomes in sepsis-induced acute respiratory distress syndrome (ARDS), focusing on which coagulopathy parameters could predict mortality and guide anticoagulant use.
  • The researchers identified specific coagulopathy markers—prothrombin time and platelet count—as significant predictors of in-hospital mortality, with patients with certain coagulopathy types showing worse oxygenation recovery.
  • Findings indicated that anticoagulants positively affected mortality and oxygenation recovery for patients with specific coagulopathy, highlighting the need for tailored treatment approaches in ARDS patients.
View Article and Find Full Text PDF

Metabolic Myopathies in the Era of Next-Generation Sequencing.

Genes (Basel)

April 2023

Université Paris Est, U955, IMRB, INSERM, APHP, Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France, Henri Mondor Hospital, 94000 Créteil, France.

Metabolic myopathies are rare inherited disorders that deserve more attention from neurologists and pediatricians. Pompe disease and McArdle disease represent some of the most common diseases in clinical practice; however, other less common diseases are now better-known. In general the pathophysiology of metabolic myopathies needs to be better understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!